Technology Innovation Institute and World Economic Forum Announce ‘Abu Dhabi Centre for Frontier Technologies’ at Davos
21.1.2026 15:30:00 CET | Business Wire | Press release
Abu Dhabi becomes home to newest Centre for the Fourth Industrial Revolution, focused on Quantum, Robotics, Space Tech and relate AI applications
The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), and the World Economic Forum (WEF) have announced the launch of the Abu Dhabi Centre for Frontier Technologies, a new Centre within WEF’s prestigious Centre for the Fourth Industrial Revolution (C4IR) Global Network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120284423/en/
Technology Innovation Institute and World Economic Forum Announce ‘Abu Dhabi Centre for Frontier Technologies’ at Davos (Photo: AETOSWire)
The collaboration was formalized during a signing ceremony on the sidelines of the World Economic Forum Annual Meeting 2026 in Davos, marking a significant step in deepening international cooperation to shape the future of frontier technologies.
Established with a clear mandate to lead breakthroughs in frontier research and development, advance global policy on emerging technologies, and foster international collaboration that moves innovation from the lab into real-world deployment, the Centre builds on the UAE’s position as a real-world testbed for innovation. Supported by an agile regulatory environment and a strong link between research, policy and execution, the UAE offers a unique platform for piloting, deploying and scaling emerging technologies at a national level - a capability that will now be amplified through the World Economic Forum’s globally connected C4IR network.
The new Centre positions Abu Dhabi as a global epicenter for pioneering research of advanced technologies, with a focus on Quantum Computing, Robotics, Propulsion & Space systems, and related AI applications. Through this strategic partnership, TII joins a globally connected innovation ecosystem designed to accelerate the responsible adoption of transformative technologies.
Dr. Najwa Aaraj, CEO of TII, said: “As frontier technologies accelerate, there is a growing imperative and opportunity to guide their responsible and impactful adoption. This Centre brings together research excellence, policy leadership and global collaboration in one platform - pushing the boundaries of frontier R&D while enabling breakthrough science to move beyond the lab into real-world application. By translating innovation into responsibly governed, scalable solutions, we are reinforcing Abu Dhabi’s role as a global hub for science, innovation and impact.”
With this announcement, Abu Dhabi strengthens the UAE’s presence within the World Economic Forum’s global C4IR network, joining a distinguished group of Centres across countries such as the US, Germany, Saudi Arabia, Japan, and India.
The addition of Abu Dhabi Centre for Frontier Technologies strengthens the C4IR Global Network’s ability to shape global technology agenda,” said Jeremy Jurgens, Managing Director, World Economic Forum. “By bringing world-class research capabilities into the Network, this Centre will support industries in translating innovation into practical, responsible solutions that advance inclusion, sustainability and trust in technology.”
The Centre aims to push the boundaries of research and development in critical frontier technologies, while showcasing Abu Dhabi’s thought leadership through proof-of-concept pilots, regulatory sandboxes, and global convenings. It will serve as both an innovation engine and a strategic platform, advancing responsible technology adoption and reinforcing the UAE’s global standing in science and innovation.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120284423/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom